A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

• Status: RECRUITING
• Trial end date: 2032-10-15

Summary

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

• Phase: PHASE3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
• Treatments: Acetaminophen; Bevacizumab; Dexamethasone; Histamine Antagonists; Histamine H2 Antagonists